|
|
|
| Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis |
| Hui-Fen Dai, Xiao-Wen Wang and Kui Zhao |
Hangzhou, China
Author Affiliations: Zhejiang University School of Medicine, Hangzhou 310058, China (Dai HF); Department of Traditional Chinese Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China (Wang XW); and PET Centre, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Zhao K)
Corresponding Author: Kui Zhao, MD, PET Centre, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Tel: 86-571-87236428; Fax: 86-571-87236431; Email: xk905@hotmail.com) |
|
|
|
|
Abstract BACKGROUND: The role of prophylactic nonsteroidal anti-inflammatory drugs (NSAIDs) for reduction of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) is debated. We performed a meta-analysis of all published randomized controlled trials to evaluate the efficacy of NSAIDs in the prevention of post-ERCP pancreatitis.
DATA SOURCES: Searches were conducted in the databases PubMed, EMBASE and the Cochrane Library. Six randomized clinical trials that fulfilled the inclusion criteria and addressed the clinical questions of this analysis were further assessed. Data were extracted by two independent observers according to predetermined criteria.
RESULTS: The risk of pancreatitis was lower in the NSAID group than in the placebo group (OR: 0.46, 95% CI: 0.32 to 0.65, P<0.0001). Two hours after ERCP, prophylactic administration of NSAIDs was associated with a lower serum amylase level (WMD: -91.09, 95% CI: -149.78 to -32.40, P=0.002), but there was no difference in mean 24-hour serum amylase values (WMD: -379.00, 95% CI: -805.75 to 47.76, P=0.08). No deaths or NSAID-related complications were noted.
CONCLUSIONS: Prophylactic administration of NSAIDs can reduce the incidence of post-ERCP pancreatitis; this administration in patients undergoing ERCP is recommended. Further randomized controlled trials are required before its introduction into routine care.
|
|
|
|
|
|
|
|
|
2009, Vol. 8 
